{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:21:31Z","timestamp":1793157691625,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi and Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jgar.2024.01.023","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T12:36:41Z","timestamp":1707309401000},"page":"407-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-7074","authenticated-orcid":false,"given":"Michael M","family":"Tunney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe S","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M","family":"Longshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.01.023_bib0001","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-0042-1758732","article-title":"Microbial epidemiology of the cystic fibrosis airways: past, present, and future","volume":"44","author":"Thornton","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2024.01.023_bib0002","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/piac052","article-title":"Opportunistic pathogens in cystic fibrosis: epidemiology and pathogenesis of lung infection","volume":"11","author":"Blanchard","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.jgar.2024.01.023_bib0003","article-title":"Antibiotic resistance in patients with cystic fibrosis: past, present, and future","volume":"12","author":"Perikleous","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2024.01.023_bib0004","doi-asserted-by":"crossref","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","article-title":"Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections","volume":"73","author":"Warner","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.01.023_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgar.2021.07.014","article-title":"In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018","volume":"27","author":"Gant","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.01.023_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01724-22","article-title":"In vitro activity of cefiderocol against extensively drug-resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019","volume":"10","author":"Karlowsky","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.01.023_bib0007","article-title":"In vitro activity of cefiderocol against meropenem-nonsusceptible Gram-negative bacilli with defined \u03b2-lactamase carriage: SIDERO-WT surveillance studies, 2014\u20132019","volume":"11","author":"Wise","year":"2023","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2024.01.023_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01990-21","article-title":"In vitro susceptibility of gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.01.023_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.01.023_bib0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2024.01.023_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04437-22","article-title":"Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, and novel darobactin analogs against multidrug-resistant Pseudomonas aeruginosa isolates from pediatric and adolescent cystic fibrosis patients","volume":"11","author":"Marner","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.01.023_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00194-23","article-title":"Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program","volume":"67","author":"Satlin","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.01.023_bib0013","first-page":"11","article-title":"In vitro activity of cefiderocol and comparators against carbapenem-resistant Gram-negative pathogens from France and Belgium","author":"Oueslati","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2024.01.023_bib0014","first-page":"12","article-title":"In vitro activity of cefiderocol against clinical Gram-negative isolates originating from Germany in 2016\/17","author":"Wohlfarth","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2024.01.023_bib0015","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015\u20132016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.01.023_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106878","article-title":"In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004\u20132020","volume":"62","author":"Lee","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.01.023_bib0017","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","article-title":"In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020","volume":"33","author":"Hawser","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.01.023_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9122473","article-title":"In vitro activity of 22 antibiotics against Achromobacter isolates from people with cystic fibrosis: are there new therapeutic options?","volume":"9","author":"Beauruelle","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.jgar.2024.01.023_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.1341","article-title":"In vitro activity of cefiderocol against US Achromobacter spp. and Burkholderia spp. clinical isolates from the SENTRY surveillance program 2020\u20132021","volume":"9","author":"Takemura","year":"2022","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:02:55Z","timestamp":1761991375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":19,"alternative-id":["S2213716524000298"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.01.023","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}